Benchmark Downgrades VolitionRx (NYSEAMERICAN:VNRX) to Hold
Benchmark Downgrades VolitionRx (NYSEAMERICAN:VNRX) to Hold
VolitionRx (NYSEAMERICAN:VNRX – Get Rating) was downgraded by stock analysts at Benchmark from a "buy" rating to a "hold" rating in a note issued to investors on Wednesday, Marketbeat reports. The analysts noted that the move was a valuation call.
据Marketbeat报道，VolitionRx(NYSEAMERICAN：VNRX-GET Rating)在周三发给投资者的一份报告中，被基准股票分析师从“买入”下调至“持有”。分析人士指出，此举是一次估值预测。
Separately, EF Hutton Acquisition Co. I began coverage on shares of VolitionRx in a research report on Monday, December 19th. They issued a "buy" rating and a $6.00 target price for the company.
另外，EF Hutton Acquisition Co.I在12月19日(星期一)的一份研究报告中开始报道VolitionRx的股票。他们对该公司的评级为“买入”，目标价为6美元。
VolitionRx Stock Performance
VolitionRx股票表现
Shares of NYSEAMERICAN:VNRX opened at $2.35 on Wednesday. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.04 and a quick ratio of 1.04. The company has a market capitalization of $134.66 million, a P/E ratio of -4.12 and a beta of 1.73. VolitionRx has a 52 week low of $1.31 and a 52 week high of $3.30.
NYSEAMERICAN：VNRX的股票周三开盘报2.35美元。该公司的债务权益比为0.94，流动比率为1.04，速动比率为1.04。该公司市值为1.3466亿美元，市盈率为-4.12，贝塔系数为1.73。VolitionRx的52周低点为1.31美元，52周高点为3.30美元。
Insider Activity at VolitionRx
VolitionRx的内幕活动
In related news, Director Martin Charles Faulkes bought 55,000 shares of the company's stock in a transaction on Friday, December 16th. The stock was bought at an average cost of $2.10 per share, with a total value of $115,500.00. Following the completion of the purchase, the director now owns 1,637,068 shares in the company, valued at approximately $3,437,842.80. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, insider Jacob Vincent Micallef acquired 25,000 shares of the firm's stock in a transaction that occurred on Monday, December 19th. The stock was purchased at an average price of $2.30 per share, for a total transaction of $57,500.00. Following the completion of the acquisition, the insider now owns 188,392 shares in the company, valued at $433,301.60. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Martin Charles Faulkes acquired 55,000 shares of the firm's stock in a transaction that occurred on Friday, December 16th. The shares were purchased at an average price of $2.10 per share, with a total value of $115,500.00. Following the acquisition, the director now owns 1,637,068 shares of the company's stock, valued at approximately $3,437,842.80. The disclosure for this purchase can be found here. Insiders bought 106,489 shares of company stock valued at $228,812 in the last ninety days. Insiders own 16.00% of the company's stock.
在相关新闻中，董事马丁·查尔斯·福克斯在12月16日(星期五)的一次交易中购买了55,000股该公司股票。这只股票是以每股2.10美元的平均成本购买的，总价值为115,500.00美元。收购完成后，董事现在拥有该公司1,637,068股，价值约3,437,842.80美元。此次收购是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可在此超链接。在其他新闻方面，内部人士雅各布·文森特·米卡利夫在12月19日星期一的一笔交易中收购了该公司25,000股股票。股票是以每股2.30美元的平均价格购买的，总交易额为57,500.00美元。收购完成后，这位内部人士现在拥有该公司188,392股，价值433,301.60美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可在以下网址获得此超链接。此外，董事马丁·查尔斯·福克斯在12月16日(星期五)的一次交易中购买了55,000股该公司股票。这些股票是以每股2.10美元的平均价格购买的，总价值为115,500.00美元。收购完成后，董事现在拥有1,637,068股公司股票，价值约3,437,842.80美元。关于这次购买的披露可以找到这里。内部人士在过去90天内买入106,489股公司股票，价值228,812美元。内部人士持有该公司16.00%的股份。
Hedge Funds Weigh In On VolitionRx
对冲基金参与VolitionRx
Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. raised its holdings in VolitionRx by 1.0% in the 1st quarter. BlackRock Inc. now owns 547,862 shares of the medical research company's stock valued at $1,650,000 after buying an additional 5,644 shares during the last quarter. State Street Corp grew its position in shares of VolitionRx by 10.0% during the 1st quarter. State Street Corp now owns 115,323 shares of the medical research company's stock worth $347,000 after buying an additional 10,500 shares during the period. Captrust Financial Advisors grew its position in shares of VolitionRx by 316.7% during the 1st quarter. Captrust Financial Advisors now owns 25,000 shares of the medical research company's stock worth $75,000 after buying an additional 19,000 shares during the period. Cowen Prime Advisors LLC grew its position in shares of VolitionRx by 83.2% during the 4th quarter. Cowen Prime Advisors LLC now owns 177,043 shares of the medical research company's stock worth $430,000 after buying an additional 80,412 shares during the period. Finally, Spectrum Asset Management Inc. NB CA acquired a new stake in shares of VolitionRx during the 4th quarter worth approximately $135,000. 10.30% of the stock is currently owned by institutional investors and hedge funds.
机构投资者和对冲基金最近调整了对该股的持有量。贝莱德股份有限公司在第一季度增持了VolitionRx 1.0%的股份。贝莱德股份有限公司现在持有这家医药研究公司547,862股股票，价值1,650,000美元，该公司在上个季度又购买了5,644股。道富银行在第一季度持有的VolitionRx股票增加了10.0%。道富集团目前持有这家医疗研究公司115,323股票，价值347,000美元，在此期间又购买了10,500股票。CapTrust Financial Advisors在第一季度将其在VolitionRx股票的头寸增加了316.7%。CapTrust Financial Advisors在此期间又购买了19,000股，现在拥有25,000股这家医疗研究公司的股票，价值75,000美元。Cowen Prime Advisors LLC在第四季度将其在VolitionRx的股票头寸增加了83.2%。Cowen Prime Advisors LLC在此期间又购买了80,412股，现在拥有177,043股这家医疗研究公司的股票，价值43万美元。最后，Spectrum Asset Management Inc.NB CA在第四季度收购了价值约13.5万美元的VolitionRx股票。10.30%的股票目前由机构投资者和对冲基金持有。
VolitionRx Company Profile
VolitionRx公司简介
(Get Rating)
(获取评级)
VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.
VolitionRX有限公司是一家跨国生命科学公司，致力于开发基于血液的癌症测试，以帮助诊断一系列癌症。它的产品包括识别和测量血液或其他体液中的核小体的核小体平台。该公司成立于1998年9月24日，总部设在内华达州亨德森。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on VolitionRx (VNRX)
- Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
- Mullen Automotive Stock Gains Momentum On Positive News
- Harley-Davidson Inc. Stock, Is It Time To Buy?
- The Bottom Is In For Meta Platforms, Volatility Is Not Over
- Analyzing Alaska Air's Recent Earnings
- 免费获取StockNews.com关于VolitionRx(VNRX)的研究报告
- 凯西·伍兹的方舟创新ETF将在2023年反弹？
- 马伦汽车公司股票因利好消息而上涨
- 哈雷-戴维森公司的股票，是时候买入了吗？
- Meta平台的底部已经到了，波动性还没有结束
- 阿拉斯加航空公司近期收益分析
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.
接收VolitionRx日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对VolitionRx和相关公司的最新新闻和分析师评级的每日简要摘要。